Expert Interview
A Second View: Discussing LLY's Mounjaro (tirzepatide) as a weight loss treatment for patients with obesity and other overweight-related health problems
Ticker(s): LLYInstitution: Mayo Clinic
- Professor of Medicine & Consultant, Division of Endocrinology, Diabetes, Metabolism, Nutrition, Department of Internal Medicine at the Mayo Clinic.
- Manages 40 patients monthly with obesity.
- His lab studies the effects of obesity and how body fat (adipose tissue) and body fat distribution influence health; research involves measuring free fatty acid release in order to relate these factors to organ and tissue function with a goal of understanding the regulation of body fat and body fat distribution, in hopes of developing novel approaches to improve the health of humans affected by obesity or excess fat.
Please describe your background and practice setting
Added By: ben_adminHow many patients with weight related health issues do you currently manage?
Added By: ben_adminHave you prescribed any approved GLP-1s to date?
Added By: ben_adminWhat do you think of Tirzepatide's clinical data?
Added By: ben_adminHow do the weight loss results compare to other GLP-1's in this space?
Added By: ben_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
